Abbott Laboratories (SWX:ABT)
Market Cap | 178.38B |
Revenue (ttm) | 34.96B |
Net Income (ttm) | 11.10B |
Shares Out | n/a |
EPS (ttm) | 6.35 |
PE Ratio | 16.06 |
Forward PE | 23.16 |
Dividend | 1.96 (1.93%) |
Ex-Dividend Date | Oct 15, 2025 |
Volume | 35 |
Average Volume | 2 |
Open | 102.00 |
Previous Close | 104.00 |
Day's Range | 102.00 - 102.00 |
52-Week Range | 92.00 - 106.00 |
Beta | 0.68 |
RSI | 1.21 |
Earnings Date | Oct 15, 2025 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial numbers in USD Financial StatementsNews

Walmart to be first US retailer to sell Abbott's continuous glucose monitor, Axios reports
Walmart will become the first U.S. retailer to sell an over-the-counter continuous glucose monitor in physical stores, as Abbott Laboratories' Lingo rolls out to more than 3,500 locations and online, ...

Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming
The market has overreacted to ABT's lowered FY2025 organic sales growth/narrowed adj. EPS, since the management continues to deliver robust numbers while building upon FY2024 outperformance. Much of i...
Peter Lynch Detailed Fundamental Analysis - ABT
Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of ...
S&P 500 Analyst Moves: ABT
The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #85 analyst pick, moving up by 1 spot. This ra...

Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength
Abbott Laboratories (NYSE: ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance . The company reported third-quarter sales of $11.37 billion, slightly mis...

These Analysts Revise Their Forecasts On Abbott Following Q3 Results
Abbott Laboratories (NYSE: ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday. The company reported third-quarter sales of $11.37 billion, slightly missing ...

These Analysts Revise Their Forecasts On Abbott Following Q3 Results
Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.
Wells Fargo Raises Abbott Laboratories (ABT) Price Target to $146 | ABT Stock News
Wells Fargo Raises Abbott Laboratories (ABT) Price Target to $146 | ABT Stock News
Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds

Salesforce mit neuen Plänen, TSMC stark, Morgan Stanley toppt Erwartungen • news
FlatexDeGiro, Sartorius, Abbott Laboratories, Bank of America, Morgan Stanley, United Airlines, Apple, Nvidia, Arm, Hims & Hers, Salesforce, Taiwan Semi.
Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Strong Organic Growth and Medical ...
Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Strong Organic Growth and Medical Devices Lead the Way
Abbott Laboratories (ABT) Sees Robust Growth in Q3 2025
Abbott Laboratories (ABT) Sees Robust Growth in Q3 2025

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.06% to 46,299.96 while the NASDAQ climbed 0.52% to 22,639....

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
Abbott Laboratories (NYSE:ABT) stock fell around 2.6% on Wednesday after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.
Q3 2025 Abbott Laboratories Earnings Call Transcript
Q3 2025 Abbott Laboratories Earnings Call Transcript
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
Abbott Laboratories' Q3 2025 Results: Steady Performance with Limited Upside
Abbott Laboratories' Q3 2025 Results: Steady Performance with Limited Upside
ABT Makes Notable Cross Below Critical Moving Average
In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $130.01, changing hands as low as $127.88 per share. Abbott Laboratories shares are c...

Abbott Laboratories Remains In Favor With London Investment Manager, New Filing Shows
Abbott Laboratories (ABT) Faces Revenue Shortfall Despite Earnings Alignment
Abbott Laboratories (ABT) Faces Revenue Shortfall Despite Earnings Alignment
Abbott Laboratories (ABT) Stock Dips After Q3 2025 Miss
Abbott Laboratories (ABT) Stock Dips After Q3 2025 Miss
Abbott Laboratories (ABT) Anticipates Earnings Surge
Abbott Laboratories (ABT) Anticipates Earnings Surge

Abbott Tightens Annual Sales Forecast As Q3 Sales Miss Expectations
Abbott Laboratories (NYSE: ABT) stock fell after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance. The company reported third-quarter sales of $11.37 billion, s...
Abbott Laboratories (ABT) Reports Mixed Q3 Results
Abbott Laboratories (ABT) Reports Mixed Q3 Results
Abbott Laboratories Q3 Earnings: Adjusted EPS of $1.30 Beats Estimates, Revenue at $11. ...
Abbott Laboratories Q3 Earnings: Adjusted EPS of $1.30 Beats Estimates, Revenue at $11.369 Billion Slightly Misses Expectations